Clinical Characteristics and Risk Factors of Carbapenem- Resistant Enterobacteriaceae: A Case-Control Study in a Tertiary Hospital in Malaysia
Main Article Content
Abstract
Introduction: Carbapenem-resistant Enterobacteriaceae (CRE) is increasingly reported worldwide causing serious threats to healthcare. This study aimed to identify the common organisms associated with CRE, the clinical characteristics and risk factors for acquiring CRE infection and colonisation among hospitalised patients. Methods: This is a matched, case-control study. Patients aged 18 years and above whom were hospitalised from January 2019 to December 2019 and had CRE isolated from clinical specimens were matched with carbapenem-susceptible controls (CSE), based on gender and age. Univariate and multivariate statistical analysis was performed. Results: Among 184 patients, Klebsiella pneumoniae was the most common organism causing CRE infection and colonisation. Chronic kidney disease (p=0.025, OR:3.12, 95% CI:1.15-8.41), urinary catheterisation (p=0.005, OR:3.67, 95% CI:1.49- 9.00), prior use of cephalosporin (p<0.001, OR:4.69, 95% CI:1.96–11.22) and beta-lactam combination agent (p<0.001, OR:7.18, 95% CI:2.98-17.26) were identified as the independent risk factors. Conclusion: Chronic kidney disease, urinary catheterisation, prior use of cephalosporin and beta-lactam combination agents were independently associated with CRE infection and colonisation. These findings enable targeting potential CRE cohorts, hence, necessitate early undertaking of prevention measures to delay the onset of CRE. A rigorous effort by antibiotic stewardship an infection control team are pivotal.
Downloads
Article Details
References
Yigit H, Queenan AM, Anderson GJ, Domenech- Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolysing beta- lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001;45(4):1151-61.
Nordmann P,Naas T & Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011;17(10):17918.
Palasubramaniam S, Karunakaran R, Gan GG, Muniandy S, Parasakthi N. Imipenem-resistance in Klebsiella pneumoniae in Malaysia due to loss of OmpK36 outer membrane protein coupled with AmpC hyperproduction. Int J Infect Dis 2007;11:472-4.
Correa L, Martino MD, Siqueira I, Pasternak J, Gales AC, Silva CV, et al. A hospital-based matched case-control study to identify clinical outcome and risk factors associated with carbapenem-resistant Klebsiella pneumoniae infection. BMC Infect Dis 2013; 13(80). doi:10.1186/1471-2334-13-80.
Garbati MA, Sakkijha H & Abushaheen A. Infections due to carbapenem-resistant Enterobacteriaceae among Saudi Arabian hospitalised patients: A matched case-control study. BioMed Res Int vol 2016:3961684. doi:10.1155/2016/3961684.
Falagas ME, Lourida P, Poulikakos P, Rafailidis PI & Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 2014;58(2):654-63.
Patel G, Huprikar S, Factor SH, Jenkins SG & Calfee DP. Outcomes of carbapenem- resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29(12):1099-106.
Ling ML, Tee YM, Tan SG, Amin IM, How KB, Tan KY, et al. Risk factors for acquisition of carbapenem resistant Enterobacteriaceae in an acute tertiary care hospital in Singapore. Antimicrob Resist Infect Control 2015 Jun 23;4:26. doi:10.1186/s13756-015-0066-3.
CLSI. M100 Performance Standards for Antimicrobial Susceptibility Testing . 29th ed. CLSI supplement M100. Wayne, PA: Clinical Laboratory Standards Institute; 2019.
Wang Q, Zhang Y, Yao X, Xian H, Liu Y, Li H, et al. Risk factors and clinical outcomes for carbapenem- resistant Enterobacteriaceae nosocomial infections. Eur J Clin Microbiol Infect Dis 2016;35(10):1679- 89.
Fang L, Lu X, Xu H, Ma X, Chen Y, Liu Y, et al. Epidemiology and risk factors for carbapenem- resistant Enterobacteriaceae colonisation and infections: Case-controlled study from an academic medical centre in a southern area of China. Pathog Dis 2019;77(4):1-8.
Schwaber MJ, Lev B, Israeli A, Solter E, Smollan G, Rubinovitch B, et al. Containment of a country- wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin Infect Dis 2011;52(7):848-55.
Giani T, Arena F, Vaggelli G, Conte V, Chiarelli A, De Angelis LH, et al. Large nosocomial outbreak of colistin-resistant, carbapenemase-producing Klebsiella pneumoniae traced to clonal expansion of an mgrb deletion mutant. J Clin Microbiol 2015;53(10):3341-4.
Kofteridis DP, Valachis A, Dimopoulou D, Maraki S, Christidou A, Mantadakis E, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonisation: A case-case-control study. J Infect Chemother 2014;20(5):293-7.
Murphy CN & Clegg S. Klebsiella pneumoniae and type 3 fimbriae: nosocomial infection, regulation and biofilm formation. Future Microbiol 2012;7(8):991-1002.
Johnson DW & Fleming SJ. The use of vaccines in renal failure. Clin Pharmacokinet 1992;22(6):434- 46.
Naqvi SB & Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis 2006;13(3):199-204.
Saminathan TA, Hooi LS, Mohd Yusoff M, Ong LM, Bavanandan S, Rodzlan Hasani WS, et al. Prevalence of chronic kidney disease and its associated factors in Malaysia; findings from a nationwide population-based cross-sectional study. BMC Nephrol 2020;2:344. doi:10.1186/ s12882-020-01966-8.
Association for Professionals in Infection Control and Epidemiology (APIC). Guide to the elimination of infections in haemodialysis. 2010. Available from: https://www.esrdnetwork.org/sites/default/files/content/pdf/regulations/APIC_Haemodialysis_.pdf
Karkar A, Bouhaha BM, Dammang ML. Infection control in haemodialysis units: A quick access to essential elements. Saudi J Kidney Dis Transplant 2014;25(3):496–519.
Marchaim D, Chopra T, Bhargava A, Bogan C, Dhar S, Hayakawa K, et al. Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: The role of antimicrobial stewardship. Infect Control Hosp Epidemiol 2012;33(8):817-30.
Li X & Ye H. Clinical and mortality risk factors in bloodstream infections with carbapenem-resistant Enterobacteriaceae. Can J Infect Dis Med Microbiol 201: 6212910. doi:10.1155/2017/6212910.
Guh AY, Bulens SN, Mu Y, Jacob JT, Reno J, Scott J, et al. Epidemiology of carbapenem-resistant Enterobacteriaceae in 7 US communities, 2012-2013. JAMA 2015;314(14):1479-87.
Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010;50(5):625- 63.
Hussein K, Raz-Pasteur A, Finkelstein R, Neuberger A, Shachor-Meyouhas Y, Oren I, et al. Impact of carbapenem resistance on the outcome of patients’ hospital-acquired bacteraemia caused by Klebsiella pneumoniae. J Hosp Infect 2013;83(4):307-13.
Ahn JY, Song JE, Kim MH, Choi H, Kim JK, Ann HW, et.al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care centre in South Korea: A matched case-control study. Am J Infect Control 2014;42(6):621-5.
Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M & Fishman NO. Risk Factors and clinical impact of Klebsiella pneumoniae carbapenemase- producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2009;30(12):1180-5.
Brennan BM, Coyle JR, Marchaim D, Pogue JM, Boehme M, Finks J, et al. Statewide surveillance of carbapenem- resistant Enterobacteriaceae in Michigan. Infect Control Hosp Epidemiol 2014;35(4):342-9.
Jiao Y, Qin Y, Liu J, Li Q, Dong Y, Shang Y, et al. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonisation and predictors of mortality: A retrospective study. Pathog Glob Health 2015;109(2):68-74.
Pournaras S, Protonotariou E, Voulgari E, Kristo I, Dimitroulia E, Vitti D, et al. Clonal spread of KPC-2 carbapenemase- producing Klebsiella pneumoniae strains in Greece. J Antimicrob Chemother 2009;64(2):348-52.
Karam G, Chastre J, Wilcox MH & Vincent JL. Antibiotic strategies in the era of multidrug resistance. Crit Care 2016;20:136. doi:10.1186/ s13054-016-1320-7.
Armand-Lefèvre L, Angebault C, Barbier F, Hamelet E, Defrance G, Ruppé E, et al. Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother 2013;57(3):1488–95.
Livermore DM. Bacterial resistance: Origins, epidemiology, and impact. Clin Infect Dis 2003;36(Suppl.1):S11–23.
Queenan AM, Bush K. Carbapenemases: The versatile β-lactamases. Clin Microbiol Rev.2007;20(3):440–58.
Rooney CM, Sheppard AE, Clark E, Davies K, Hubbard ATM, Sebra R, et al. Dissemination of multiple carbapenem resistance genes in an in vitro gut model simulating the human colon. J Antimicrob Chemother 2019;74(7):1876-83.
Viale P, Tumietto F, Giannella M, Bartoletti M, Tedeschi S, Ambretti S, et al. Impact of a hospital-wide multifaceted program for reducing carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy. Clin Microbiol Infect 2015;21(3):242-7.